A detailed history of Pnc Financial Services Group, Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 34 shares of ALDX stock, worth $162. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34
Previous 34 -0.0%
Holding current value
$162
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$3.25 - $4.72 $110 - $160
34 New
34 $0
Q3 2022

Nov 10, 2022

BUY
$3.8 - $7.74 $934 - $1,904
246 New
246 $1,000
Q2 2022

Aug 12, 2022

SELL
$2.43 - $4.85 $97 - $194
-40 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$3.25 - $5.17 $130 - $206
40 New
40 $0
Q4 2021

Feb 11, 2022

SELL
$3.5 - $9.63 $868 - $2,388
-248 Closed
0 $0
Q3 2021

Nov 05, 2021

BUY
$7.94 - $11.31 $1,564 - $2,228
197 Added 386.27%
248 $2,000
Q2 2021

Aug 06, 2021

BUY
$10.44 - $14.85 $532 - $757
51 New
51 $0

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $279M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.